VANNUCCHI, ALESSANDRO MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 47.948
EU - Europa 33.828
AS - Asia 22.120
SA - Sud America 3.218
Continente sconosciuto - Info sul continente non disponibili 991
AF - Africa 714
OC - Oceania 509
AN - Antartide 1
Totale 109.329
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 47.042
RU - Federazione Russa 9.181
PL - Polonia 8.105
IT - Italia 6.860
SG - Singapore 5.902
CN - Cina 5.247
HK - Hong Kong 3.219
BR - Brasile 2.575
VN - Vietnam 2.334
IE - Irlanda 2.112
KR - Corea 2.069
SE - Svezia 1.805
DE - Germania 1.116
FI - Finlandia 1.024
FR - Francia 964
GB - Regno Unito 764
IN - India 752
UA - Ucraina 640
CA - Canada 573
AU - Australia 485
JO - Giordania 463
CH - Svizzera 401
BD - Bangladesh 388
ID - Indonesia 333
AR - Argentina 273
TR - Turchia 273
JP - Giappone 240
NL - Olanda 217
ES - Italia 200
IQ - Iraq 159
MX - Messico 141
CI - Costa d'Avorio 133
ZA - Sudafrica 117
PK - Pakistan 115
NG - Nigeria 103
EC - Ecuador 101
AT - Austria 97
EG - Egitto 88
PH - Filippine 70
CO - Colombia 63
MA - Marocco 61
SA - Arabia Saudita 61
MY - Malesia 56
BE - Belgio 51
TW - Taiwan 51
IR - Iran 49
VE - Venezuela 47
PY - Paraguay 46
UZ - Uzbekistan 46
GR - Grecia 45
CL - Cile 42
AE - Emirati Arabi Uniti 39
CZ - Repubblica Ceca 37
TN - Tunisia 37
JM - Giamaica 36
DZ - Algeria 31
KE - Kenya 31
NP - Nepal 30
PE - Perù 30
IL - Israele 27
KZ - Kazakistan 24
UY - Uruguay 24
AL - Albania 23
NZ - Nuova Zelanda 23
RO - Romania 23
TT - Trinidad e Tobago 23
BJ - Benin 22
DO - Repubblica Dominicana 22
ET - Etiopia 22
CR - Costa Rica 21
HN - Honduras 21
TH - Thailandia 20
BG - Bulgaria 18
HU - Ungheria 17
SK - Slovacchia (Repubblica Slovacca) 17
SV - El Salvador 17
OM - Oman 16
LK - Sri Lanka 15
SC - Seychelles 15
LT - Lituania 14
AZ - Azerbaigian 13
BO - Bolivia 13
GT - Guatemala 13
LB - Libano 13
NO - Norvegia 12
BH - Bahrain 11
DK - Danimarca 11
SN - Senegal 11
SY - Repubblica araba siriana 11
KG - Kirghizistan 10
KW - Kuwait 10
MU - Mauritius 10
PT - Portogallo 10
BY - Bielorussia 9
QA - Qatar 9
RS - Serbia 9
GE - Georgia 8
HR - Croazia 8
SI - Slovenia 8
AM - Armenia 7
Totale 108.200
Salva come PNG Salva come JPEG
Città #
Warsaw 8.059
Santa Clara 7.853
Ashburn 5.532
Fairfield 4.759
Singapore 4.198
Hong Kong 2.647
Woodbridge 2.166
Dublin 2.105
Seattle 2.052
Seoul 2.028
Chandler 1.854
Cambridge 1.814
Houston 1.798
Wilmington 1.582
Hefei 1.365
San Jose 1.285
Milan 1.234
Jacksonville 1.002
Beijing 880
Altamura 822
Lawrence 793
Los Angeles 750
Ann Arbor 733
Ho Chi Minh City 729
Princeton 660
Buffalo 600
Lauterbourg 598
The Dalles 575
Hanoi 563
Rome 551
Boston 479
Florence 478
Dallas 469
Moscow 464
Helsinki 419
New York 419
Melbourne 409
Mumbai 382
Bern 380
Council Bluffs 361
Boardman 358
Amman 328
San Diego 275
Medford 256
Jakarta 227
Munich 221
São Paulo 213
Shanghai 200
Kent 199
Clifton 172
Tokyo 171
Bremen 164
London 159
Waltham 159
Naples 158
Frankfurt am Main 139
Bologna 136
Chicago 134
Abidjan 133
Turin 132
Dong Ket 128
Phoenix 124
Orem 120
Toronto 120
Izmir 118
Paris 108
Da Nang 102
Montreal 102
Redondo Beach 102
Abuja 97
Turku 95
Brooklyn 93
Barcelona 89
Lappeenranta 89
Norwalk 89
Haiphong 85
Figino 83
Rio de Janeiro 82
San Francisco 80
Hillsboro 78
Miano 77
Vienna 75
Palermo 74
Denver 73
Guangzhou 71
Atlanta 67
Chennai 66
Falls Church 66
Bari 65
Bengaluru 65
Brescia 61
Baghdad 60
Belo Horizonte 60
Catania 57
Venice 56
Verona 56
Andover 54
Biên Hòa 53
Shenzhen 50
Pinole 49
Totale 73.020
Salva come PNG Salva come JPEG
Nome #
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management 2.247
JAK Inhibition with Ruxolitinib versus Best Available Therapyfor Myelofibrosis 539
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 446
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 391
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 385
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations 363
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis:an international study. 363
HDAC1 controls CIP2A transcription in human colorectal cancer cells 362
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells 354
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 347
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 346
GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086 345
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN 345
Essential Thrombocythemia 344
Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial 343
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). 342
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 335
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 334
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 334
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation 333
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives 331
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 330
EZH2 mutational status predicts poor survival in myelofibrosis. 327
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 325
A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. 323
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. 320
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 319
Advances in understanding and management of myeloproliferative neoplasms 319
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 318
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. 316
Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. 309
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer 308
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium 308
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 307
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 306
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 305
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 305
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. 304
Thrombocytosis and leukocytosis interactions in vascular complications of essential thrombocythemia 304
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 300
Chronic myeloproliferative neoplasms: a collaborative approach. 299
Role of miR-34a-5p in hematopoietic progenitor cells proliferation and fate decision: Novel insights into the pathogenesis of primary myelofibrosis 296
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: An observational, hypothesis-generating study 292
Feasibility of a workflow for the molecular characterization of single cells by next generation sequencing 291
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 287
Cardiovascular events and intensity of treatment in polycythemia vera. 285
Effect of mutation order on myeloproliferative neoplasms 283
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 279
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. 278
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. 276
FLT3-mediated p38-MAPK activation participates in the control ofmegakaryopoiesis in primary myelofibrosis. 275
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. 275
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 274
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis 273
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. 272
Characterisation and discovery of novel miRNAs andmoRNAs in JAK2V617F mutated SET2 cells 271
Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells 271
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms 269
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 269
MPN Score 265
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis 265
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis 263
[GM-CSF: its clinical administration; the treatment of aplasia] 262
Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms. 262
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. 262
Risk models in myelofibrosis—the past, present, and future 261
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants 260
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 251
Clinical significance of genetic aberrations in secondary acute myeloid leukemia 250
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 249
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 248
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis 247
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk ofsplanchnic vein thrombosis. 243
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group 242
Spectrum of ASXL1 mutations in primary myelofibrosis: Prognostic impact of the ASXL1 p.G646Wfs∗12 mutation 242
JAK2V617F-homozigosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant clone 236
The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes. 234
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 230
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 230
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 230
Calreticulin affects hematopoietic stem/progenitor cell fate by impacting erythroid and megakaryocytic differentiation 228
Overexpression of microRNA-16-2 contributes to the abnormalerythropoiesis in polycythemia vera. 227
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 227
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. 224
First report of FIP1L1-PDGFR alpha-positive eosinophilic granulomatosis with polyangiitis 223
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: A snapshot of 1144 patients in the JUMP trial 221
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 220
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 218
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 218
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: Pathogenetic insight and diagnostic value 217
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. 216
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 210
Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis 209
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis 208
Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis 207
From leeches to personalized medicine: Evolving concepts in the management of polycythemia vera 206
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 205
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 202
Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling, human myelofibrosis 201
The european hematology association roadmap for european hematology research: A consensus document 201
Totale 30.317
Salva come PNG Salva come JPEG
Categoria #
all - tutte 308.304
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 308.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.870 123 347 366 150 113 150 144 426 194 140 618 1.099
2022/20239.800 1.017 2.020 416 748 702 1.719 1.120 494 739 96 265 464
2023/20243.735 159 406 686 194 330 467 115 713 67 261 188 149
2024/202526.230 899 2.756 1.748 3.657 6.590 3.351 722 1.440 1.656 921 1.066 1.424
2025/202634.822 3.258 4.605 3.534 3.307 3.192 1.340 3.759 1.710 2.135 2.067 1.247 4.668
2026/20272.281 2.281 0 0 0 0 0 0 0 0 0 0 0
Totale 109.329